Skip to content

Inhibin B/AFC Ratio for Ovarian Response

Assessment of Ovarian Responsiveness Through AMH/AFC and Inhibin B/AFC Ratio

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06292806
Enrollment
144
Registered
2024-03-05
Start date
2024-03-01
Completion date
2025-12-31
Last updated
2024-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female, IVF, Ovulation Disorder

Brief summary

Ovarian response to gonadotropin stimulation plays a major role in the success of in vitro fertilization (IVF). Anti-müllerian hormone (AMH), inhibin B, and antral follicle count (AFC) are ovarian reserve markers and also predictors of the ovarian response, as they correlate with the number of oocytes retrieved. Ovarian responsiveness can also be assessed through the Follicular Output Rate (FORT), which evaluates the proportion of follicles that developed during stimulation by the ratio of PFC (preovulatory follicle count) to AFC. FORT highlights that some follicles do not respond to the FSH; therefore, this project proposes an endocrinological approach to this issue by relating AFC to inhibin B and AMH ㅡ hormones produced by granulosa cells, but at different stages of folliculogenesis and with endocrine and paracrine functions, respectively. The inhibin B/AFC and AMH/AFC ratios correlated with FORT and the number of oocytes retrieved may help elucidate the mechanisms involved in follicular responsiveness. A prospective cohort study will be conducted with patients of the Insemine Center for Human Reproduction. Antral follicle count and AMH measurement will be performed before IVF cycle initiation, and inhibin B measurement will be carried out on a blood sample collected on the fifth day of ovarian stimulation. The primary outcomes will be the Follicular Output Rate (FORT) and the number of oocytes retrieved. Secondary outcomes include the number of metaphase II oocytes, oocyte quality, fertilization rate and embryo quality.

Interventions

DRUGFSH-R

controlled ovarian stimulation for IVF

Sponsors

Insemine Humen Reproduction Centre
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* first IVF; * without severe male factor involved.

Exclusion criteria

* Patients with endometrioma; * ovarian cyst; * AMH \< 0.5 ng/ml; * increased serum TSH (thyroid-stimulating hormone) or prolactin levels; * endocrinopathies; * previous oophorectomy; * failure to visualize one of the ovaries on ultrasound.

Design outcomes

Primary

MeasureTime frame
serum Inhibin B levelsDay 1 and Day 5 of controlled ovarian stimulation
serum Anti Mullerian Hormone levelsDay 1 and Day 5 of controlled ovarian stimulation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026